SARS-CoV-2 Mpro-IN-43
SARS-CoV-2 Mpro-IN-43 (Compound 1) is a coronavirus main protease (Mpro) inhibitor (IC50: 72 μM) . SARS-CoV-2 Mpro-IN-43 interacts with key residues in the active site of Mpro via non-covalent binding, exerting its anti-coronavirus effect. SARS-CoV-2 Mpro-IN-43 exhibits moderate to low cytotoxicity, with CC50 values of 13.24, 41.02, and 42.26 µM in HaCaT, HEK293T, and HepG2 cells, respectively. SARS-CoV-2 Mpro-IN-43 can be used in anti-SARS-CoV-2 research[1].
Product Specifications
UNSPSC
12352005
Target
SARS-CoV; Virus Protease
Related Pathways
Anti-infection
Field of Research
Infection; Inflammation/Immunology
Smiles
S=C(N1CCN(CC2=CC(F)=C(F)C=C2F)CC1)S[C@H](C3=CCOC3=O)C[C@@H]4C(CC[C@]5([H])[C@](C)(CO)[C@H](O)CC[C@@]45C)=C
Molecular Formula
C32H41F3N2O4S2
Molecular Weight
638.80
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD106 / VCAM1 (B-K9), CF568 conjugate, 0.1mg/mL
Eosinophil Peroxidase (AHE-1), CF647 conjugate, 0.1mg/mL
CD269 / TNFRSF17 / BCMA (B-Cell Maturation Protein) (BCMA/2366), CF594 conjugate, 0.1mg/mL
Chromogranin A / CHGA (Neuroendocrine Marker) (CHGA/1773R), CF594 conjugate, 0.1mg/mL
